2/19/2008

Sanofi-Aventis announced that the FDA has cleared the oral-solution version of Xyzal, its allergy treatment co-developed with Belgium-based UCB. The drug's oral formulation and tablet form, which was approved last year, can now be used by adults and children older than 6.

Full Story:
CNNMoney

Related Summaries